Critical Path Institute (C-Path) and the Coalition Against Major Diseases (CAMD)
Critical Path Institute (C-Path) is an independent, non-profit organization which creates collaborations among scientists from government regulators (FDA, European Medicines Agency (EMA), and Japanese Pharmaceutical and Medical Devices Agency (PMDA)) and the pharmaceutical industry to improve testing methods and processes used to evaluate the safety and effectiveness of new medicines. These collaborative consortia also include scientists from academic institutions and representatives from patient advocacy organizations. Within C-Path is the Coalition Against Major Diseases (CAMD) whose mission is to accelerate the development of therapies for neurodegenerative diseases such as Alzheimer’s Disease (AD) by advancing tools to be used in drug development for regulatory approval. CAMD has created and implemented AD data standards, created a clinical trial database, and received EMA approval for the first imaging biomarkers for AD. See http://c-path.org/programs/camd/.